咪唑-1-基-(9-苯氧基-吩嗪-1-基)-甲酮 | 1027729-73-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 咪唑-1-基-(9-苯氧基-吩嗪-1-基)-甲酮
• 英文名称: Imidazol-1-yl-(9-phenoxy-phenazin-1-yl)-methanone
• 英文别名: Imidazol-1-yl-(9-phenoxyphenazin-1-yl)methanone
• CAS: 1027729-73-2
• 化学式: C₂₂H₁₄N₄O₂
• 分子量: 366.379
• InChiKey: IGBRZHSOELFVBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  69.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N,N-双(3-氨丙基)甲胺 、 咪唑-1-基-(9-苯氧基-吩嗪-1-基)-甲酮 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 N-[3-[methyl-[3-[(9-phenoxyphenazine-1-carbonyl)amino]propyl]amino]propyl]-9-phenoxyphenazine-1-carboxamide
  参考文献：
  名称：

  Bis(phenazine-1-carboxamides):  Structure−Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs

  摘要：

  Ring-substituted bis(phenazine-1-carboxamides), linked by a -(CH2)(3)NMe(CH2)(3)- chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia; The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g,, Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 mu M and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 mu M, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines ton average 9.5-fold more active in the HT29 line than in the cell line, panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular, the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.

  DOI：

  10.1021/jm990423f
• 作为产物：
  描述：

  2-溴-3-硝基苯甲酸 在 copper(l) chloride N-乙基吗啉 、 sodium hydroxide 、 sodium tetrahydroborate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 52.5h， 生成 咪唑-1-基-(9-苯氧基-吩嗪-1-基)-甲酮
  参考文献：
  名称：

  Bis(phenazine-1-carboxamides):  Structure−Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs

  摘要：

  Ring-substituted bis(phenazine-1-carboxamides), linked by a -(CH2)(3)NMe(CH2)(3)- chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia; The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g,, Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 mu M and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 mu M, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines ton average 9.5-fold more active in the HT29 line than in the cell line, panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular, the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.

  DOI：

  10.1021/jm990423f

文献信息

• Bis(phenazine-1-carboxamides):  Structure−Activity Relationships for a New Class of Dual Topoisomerase I/II-Directed Anticancer Drugs
  作者：Julie A. Spicer、Swarna A. Gamage、Gordon W. Rewcastle、Graeme J. Finlay、David J. A. Bridewell、Bruce C. Baguley、William A. Denny

  DOI：10.1021/jm990423f

  日期：2000.4.6

  Ring-substituted bis(phenazine-1-carboxamides), linked by a -(CH2)(3)NMe(CH2)(3)- chain, were prepared from the corresponding substituted phenazine-1-carboxylic acids by reaction of the intermediate imidazolides with bis(3-aminopropyl)methylamine. The compounds were evaluated for growth inhibitory activity in a panel of tumor cell lines, including P388 leukemia, Lewis lung carcinoma, and wild-type (JL(C)) and mutant (JL(A) and JL(D)) forms of human Jurkat leukemia; The latter mutant lines are resistant to topoisomerase (topo) II targeted agents because of lower levels of the enzyme. Analogues with small, lipophilic substituents (e.g,, Me, Cl) at the 9-position were the most potent inhibitors, superior to the corresponding dimeric bis(acridine-4-carboxamides) (bis-DACA analogues). Several of the compounds were preferentially (up to 2-fold) more cytotoxic toward the mutant Jurkat lines than the wild-type. To test whether this selectivity was related to topoisomerase action, the most potent of the compounds (9-methyl) was evaluated in a cell-free system. It poisoned topo I at drug concentrations of 0.25 and 0.5 mu M and inhibited the catalytic activity of both topo I and topo II at concentrations of 1 and 5 mu M, respectively. Results from the NCI human tumor cell line panel showed the compounds had preferential activity toward colon tumor lines ton average 9.5-fold more active in the HT29 line than in the cell line, panel as a whole). Several analogues produced significant growth delays in the relatively refractory subcutaneous colon 38 tumor model in vivo. In particular, the 9-methyl compound was substantially more potent in this tumor model than the clinical dual topo I/II poison DACA (total dose 90 versus 400 mg/kg) with comparable activity. The bis(phenazine-1-carboxamides) are a new and interesting class of dual topo I/II-directed anticancer drugs.